Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386804037> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4386804037 abstract "Many patients with human epidermal growth factor receptor-2-positive metastatic breast cancer (HER2+ mBC) require subsequent lines of therapy (LOTs) after being treated with pertuzumab and trastuzumab-based regimens in the first line (1L). Although the efficacy of the second-line (2L) therapies has been demonstrated in clinical trials, the real-world effectiveness of these treatments is understudied. This retrospective cohort study assessed the real-world treatment patterns and outcomes for patients with HER2+ mBC following 1L therapy with pertuzumab and trastuzumab-based regimens in the United States (US) during 2015-2019.Adults with HER2+ mBC in the US who initiated 1L pertuzumab and trastuzumab-based regimens between 01/01/2015 and 09/30/2019 and had ≥ 60 days of follow-up after 1L initiation were identified from the IQVIA Oncology Electronic Medical Records database. The regimens utilized in 2L following 1L pertuzumab and trastuzumab-based regimens were described. Median treatment duration and time to treatment failure were reported for 2L based on Kaplan-Meier analyses.Of the 710 eligible patients who received pertuzumab and trastuzumab-based regimens in 1L (median age: 57.0 years [interquartile range: 48.0-65.0]; median follow-up: 20.3 months; median 1L duration: 15.3 months), 222 (31.3%) initiated 2L. The most common regimens in 2L were ado-trastuzumab emtansine (T-DM1)-based regimens (n = 159 [71.6%]), followed by lapatinib-based (n = 21 [9.5%]) and neratinib-based (n = 18 [8.1%]) regimens. The median treatment duration and time to treatment failure were 5.9 (95% CI: 5.0, 8.7) and 8.6 (7.3, 11.5) months, respectively, among patients initiating 2L, and 5.7 (4.7, 7.8) and 7.9 (6.5, 10.0) months among those receiving 2L T-DM1.Most patients with HER2+ mBC requiring additional treatments after 1L pertuzumab and trastuzumab-based regimens utilized T-DM1 in 2L during 2015-2019. The short median treatment duration and time to treatment failure highlight an unmet need that can potentially be fulfilled by recently approved treatment options." @default.
- W4386804037 created "2023-09-17" @default.
- W4386804037 creator A5011633606 @default.
- W4386804037 creator A5043134141 @default.
- W4386804037 creator A5060607239 @default.
- W4386804037 creator A5066131145 @default.
- W4386804037 creator A5084512170 @default.
- W4386804037 date "2023-09-16" @default.
- W4386804037 modified "2023-09-26" @default.
- W4386804037 title "Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer" @default.
- W4386804037 cites W2078454159 @default.
- W4386804037 cites W2110444464 @default.
- W4386804037 cites W2125401809 @default.
- W4386804037 cites W2137228442 @default.
- W4386804037 cites W2141546964 @default.
- W4386804037 cites W2144433586 @default.
- W4386804037 cites W2159967578 @default.
- W4386804037 cites W2329854883 @default.
- W4386804037 cites W2716077658 @default.
- W4386804037 cites W2802528458 @default.
- W4386804037 cites W2885273486 @default.
- W4386804037 cites W2887418167 @default.
- W4386804037 cites W2892067291 @default.
- W4386804037 cites W2979003071 @default.
- W4386804037 cites W2995808512 @default.
- W4386804037 cites W2996630100 @default.
- W4386804037 cites W3015126839 @default.
- W4386804037 cites W3043096450 @default.
- W4386804037 cites W3094613301 @default.
- W4386804037 cites W3134342541 @default.
- W4386804037 cites W3153222535 @default.
- W4386804037 cites W3199507901 @default.
- W4386804037 cites W4221053062 @default.
- W4386804037 cites W4280568195 @default.
- W4386804037 cites W4281675214 @default.
- W4386804037 cites W4281786463 @default.
- W4386804037 cites W4311116389 @default.
- W4386804037 doi "https://doi.org/10.1007/s40487-023-00241-8" @default.
- W4386804037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37715853" @default.
- W4386804037 hasPublicationYear "2023" @default.
- W4386804037 type Work @default.
- W4386804037 citedByCount "0" @default.
- W4386804037 crossrefType "journal-article" @default.
- W4386804037 hasAuthorship W4386804037A5011633606 @default.
- W4386804037 hasAuthorship W4386804037A5043134141 @default.
- W4386804037 hasAuthorship W4386804037A5060607239 @default.
- W4386804037 hasAuthorship W4386804037A5066131145 @default.
- W4386804037 hasAuthorship W4386804037A5084512170 @default.
- W4386804037 hasBestOaLocation W43868040371 @default.
- W4386804037 hasConcept C121608353 @default.
- W4386804037 hasConcept C126322002 @default.
- W4386804037 hasConcept C143998085 @default.
- W4386804037 hasConcept C2775930923 @default.
- W4386804037 hasConcept C2777329042 @default.
- W4386804037 hasConcept C2778087150 @default.
- W4386804037 hasConcept C2779413316 @default.
- W4386804037 hasConcept C2779786085 @default.
- W4386804037 hasConcept C2781164504 @default.
- W4386804037 hasConcept C530470458 @default.
- W4386804037 hasConcept C71924100 @default.
- W4386804037 hasConceptScore W4386804037C121608353 @default.
- W4386804037 hasConceptScore W4386804037C126322002 @default.
- W4386804037 hasConceptScore W4386804037C143998085 @default.
- W4386804037 hasConceptScore W4386804037C2775930923 @default.
- W4386804037 hasConceptScore W4386804037C2777329042 @default.
- W4386804037 hasConceptScore W4386804037C2778087150 @default.
- W4386804037 hasConceptScore W4386804037C2779413316 @default.
- W4386804037 hasConceptScore W4386804037C2779786085 @default.
- W4386804037 hasConceptScore W4386804037C2781164504 @default.
- W4386804037 hasConceptScore W4386804037C530470458 @default.
- W4386804037 hasConceptScore W4386804037C71924100 @default.
- W4386804037 hasFunder F4320307770 @default.
- W4386804037 hasLocation W43868040371 @default.
- W4386804037 hasLocation W43868040372 @default.
- W4386804037 hasOpenAccess W4386804037 @default.
- W4386804037 hasPrimaryLocation W43868040371 @default.
- W4386804037 hasRelatedWork W2481553405 @default.
- W4386804037 hasRelatedWork W2905960639 @default.
- W4386804037 hasRelatedWork W2953529044 @default.
- W4386804037 hasRelatedWork W3013160810 @default.
- W4386804037 hasRelatedWork W3083051559 @default.
- W4386804037 hasRelatedWork W3088751691 @default.
- W4386804037 hasRelatedWork W3090684381 @default.
- W4386804037 hasRelatedWork W4205117006 @default.
- W4386804037 hasRelatedWork W4206299960 @default.
- W4386804037 hasRelatedWork W4386804037 @default.
- W4386804037 isParatext "false" @default.
- W4386804037 isRetracted "false" @default.
- W4386804037 workType "article" @default.